Literature DB >> 6861791

Pharmacokinetics of dihydroergosine in rats after intravenous and oral administration.

A Mrhar, Z Kopitar, F Kozjek, L Krusic, A Lenardic.   

Abstract

Wistar rats received an intravenous dose of 20 micrograms/kg and an oral does of 40 micrograms/kg 3H-Dihydroergosine. Concentrations of radioactivity were measured in plasma, bile, urine, and faeces, and pharmacokinetical parameters of an open two compartment model were calculated. After intravenous injection and oral administration 3H-Dihydroergosine is rapidly lost from the central compartment with distribution rate constants alpha = 0.889 h-1 and beta = 0.722 h-1, respectively. Biological half life in the elimination phase after both application is nearly the same t 1/2 = 13.6 h. The volume of central compartment is Vc = 3.075 l/kg and the volume of distribution Vd beta = 30.75 l/kg. The fraction of 3H-Dihydroergosine absorbed after oral administration, calculated from areas under the curves upon oral and intravenous administration, is 31%. The percentage of 3H-radioactivity eliminated with bile was 98.3% of the dose within 72 hours after intravenous and 29.3% after oral administration. The main portion of the administered 3H-radioactivity was recovered in faeces -66.1% after intravenous and 81.3% after oral administration, while only 17.4% and 4.9% of the administered dose was eliminated in the urine within 120 hours, respectively.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861791     DOI: 10.1007/BF03189576

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  2 in total

1.  Bioavailability of dihydroergosine in healthy volunteers.

Authors:  P Cvelbar; J Culig; Z Kopitar; A Lenardic; J U Smerkolj; M Zorz
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jan-Mar       Impact factor: 2.441

2.  Dihydroergosine pharmacokinetic modelling and simulation.

Authors:  R Karba; A Mrhar; F Kozjek; F Bremsak; Z Kopitar; A Lenardic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.